Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

2018160 citationsJournal Articlegold Open Access

Authors

David R. Lynch · Children's Hospital of Philadelphia

Jennifer Farmer · Friedreich's Ataxia Research Alliance

Lauren Hauser · Children's Hospital of Philadelphia

Ian A. Blair · Translational Therapeutics (United States)

Qing Qing Wang · University of Pennsylvania

Clementina Mesaros · University of Pennsylvania

Nathaniel W. Snyder

Abstract

Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function. Therefore, omaveloxolone treatment is being examined in greater detail at 150 mg/day for Friedreich ataxia.

Topics & Keywords

Genetic Neurodegenerative Diseases Mitochondrial Function and Pathology Fibromyalgia and Chronic Fatigue Syndrome Research

Publication Details

Published in: Annals of Clinical and Translational Neurology

Volume 6, Issue 1, pp. 15-26

DOI: 10.1002/acn3.660

Field-Weighted Citation Impact: 6.38

Command Palette

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

Authors

Abstract

Topics & Keywords

Publication Details